Financial Ratios

SUVEN LIFE SCIENCES LTD.

NSE : SUVENBSE : 530239ISIN CODE : INE495B01038Industry : Pharmaceuticals & DrugsHouse : Private
BSE101.902.5 (+2.52 %)
PREV CLOSE ( ) 99.40
OPEN PRICE ( ) 102.00
BID PRICE (QTY) 101.00 (199)
OFFER PRICE (QTY) 101.95 (250)
VOLUME 7592
TODAY'S LOW / HIGH ( )100.10 103.00
52 WK LOW / HIGH ( )45.01 128.79
NSE100.800.85 (+0.85 %)
PREV CLOSE( ) 99.95
OPEN PRICE ( ) 100.00
BID PRICE (QTY) 100.70 (259)
OFFER PRICE (QTY) 100.80 (1442)
VOLUME 56903
TODAY'S LOW / HIGH( ) 100.00 101.90
52 WK LOW / HIGH ( )45.15 129
Select year
ParticularsMar2023Mar2022Mar2021Mar2020Mar2019
Operational & Financial Ratios
   Earnings Per Share (Rs)-0.92-2.49-1.78-1.083.08
   CEPS(Rs)-0.62-2.02-1.32-0.693.87
   DPS(Rs)0.000.000.000.001.50
   Book NAV/Share(Rs)39.1432.7428.6630.4631.56
   Tax Rate(%)0.000.0019.0446.9738.04
Margin Ratios
   Core EBITDA Margin(%)-203.20-308.41-225.92-244.6318.24
   EBIT Margin(%)-144.81-300.61-200.64-176.1822.81
   Pre Tax Margin(%)-148.66-306.04-207.41-179.9322.14
   PAT Margin (%)-148.66-306.04-167.92-95.4113.72
   Cash Profit Margin (%)-100.33-268.95-135.67-66.4918.69
Performance Ratios
   ROA(%)-2.62-6.65-4.47-2.594.68
   ROE(%)-3.03-8.62-6.02-3.486.18
   ROCE(%)-2.95-8.10-6.82-6.409.98
   Asset Turnover(x)0.020.020.030.030.34
   Sales/Fixed Asset(x)0.160.160.190.251.38
   Working Capital/Sales(x)0.060.210.160.341.07
Efficiency Ratios
   Fixed Capital/Sales(x)6.386.355.344.040.73
   Receivable days28.3847.1554.6062.2241.00
   Inventory Days0.002.533.830.000.00
   Payable days169.67
Valuation Parameters
   PER(x)0.000.000.000.0078.07
   PCE(x)-77.81-42.33-49.00-28.4262.20
   Price/Book(x)1.242.832.460.708.27
   Yield(%)0.000.000.000.000.57
   EV/Net Sales(x)65.22113.6263.7218.9611.63
   EV/Core EBITDA(x)-46.32-38.53-37.84-12.8741.88
   EV/EBIT(x)-45.04-37.80-31.76-10.7651.00
   EV/CE(x)0.932.321.690.545.97
   M Cap / Sales78.07113.8566.4818.9011.62
Growth Ratio
   Net Sales Growth(%)14.31-12.12-6.50-94.95-54.31
   Core EBITDA Growth(%)45.42-53.89-6.92-126.75-69.44
   EBIT Growth(%)44.94-31.66-6.49-138.98-72.26
   PAT Growth(%)44.47-60.16-64.56-135.09-75.26
   EPS Growth(%)62.98-40.22-64.56-135.09-75.26
Financial Stability Ratios
   Total Debt/Equity(x)0.000.000.000.010.01
   Current Ratio(x)3.401.571.831.413.05
   Quick Ratio(x)3.401.571.831.413.05
   Interest Cover(x)-37.62-55.35-29.65-47.0034.25
   Total Debt/Mcap(x)0.000.000.000.010.00

© NIRMAL BANG. All rights reserved

Designed , Developed & Content Powered by Accord Fintech Pvt. Ltd.

Open an Account
FOR AFREE *DEMAT & BROKING ACCOUNT

Please fill in the details below

Close X

(Note - You will receive a call from our sales executive)

CLOSE X

RISK DISCLOSURES ON DERIVATIVES

  • 9 out of 10 individual traders in equity Futures and Options Segment, incurred net losses.
  • On an average, loss makers registered net trading loss close to ₹ 50,000.
  • Over and above the net trading losses incurred, loss makers expended an additional 28% of net trading losses as transaction costs.
  • Those making net trading profits, incurred between 15% to 50% of such profits as transaction cost.

Source:

1. SEBI study dated January 25, 2023 on “Analysis of Profit and Loss of Individual Traders dealing in equity Futures and Options (F&O) Segment”, wherein Aggregate Level findings are based on annual Profit/Loss incurred by individual traders in equity F&O during FY 2021-22.